Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

<i>Background and Objectives:</i> Patients with human epidermal growth factor receptor 2 (HER2) -positive, hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) usually undergo trastuzumab emtansine (T-DM1) therapy in subsequent lines. Combining endocrine therapy (ET) with T-DM1 can...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Oğuzcan Kınıkoğlu, Hatice Odabas, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yıldırım, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yıldırım, Nedim Turan
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2024-06-01
סדרה:	Medicina
נושאים:	metastatic breast cancer trastuzumab emtansine endocrine therapy pertuzumab plus trastuzumab
גישה מקוונת:	https://www.mdpi.com/1648-9144/60/6/951
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!